List of Belrapzo drug patents

Belrapzo is owned by Eagle Pharms.

Belrapzo contains Bendamustine Hydrochloride.

Belrapzo has a total of 7 drug patents out of which 0 drug patents have expired.

Belrapzo was authorised for market use on 15 May, 2018.

Belrapzo is available in solution;iv (infusion) dosage forms.

Belrapzo can be used as for the treatment of patients with indolent b-cell non-hodgkin lymphoma; for the treatment of patients with chronic lymphocytic leukemia, for the treatment of patients with chronic lymphocytic leukemia; for the treatment of patients with indolent b-cell non-hodgkin lymphoma.

The generics of Belrapzo are possible to be released after 11 August, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 EAGLE PHARMS Bendamustine pharmaceutical compositions
Jan, 2026

(2 years from now)

US9265831 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(8 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(8 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(8 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(8 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(8 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine
Aug, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 7, 2022

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 May, 2018

Treatment: For the treatment of patients with chronic lymphocytic leukemia; For the treatment of patients with indolent b-cell non-hodgkin lymphoma

Dosage: SOLUTION;IV (INFUSION)

How can I launch a generic of BELRAPZO before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic